NASDAQ:AGIO

Agios Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy AGIO

*Your capital is at risk

$27.68

+1.17 (+4.41%)

At Close: Jun 03, 2026

Agios Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 4.64. In total, the insiders bought 987.62K and sold 86.14K AGIO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	4.64
● Buy	987.62K shares
● Sell	86.14K shares
70% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Mar 02, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 02, 2026 Sell	Common stock S-Sale	Washburn Theodore James Jr. Principal Accounting Officer	Officer	798 Value: $23.1K
Mar 02, 2026 Buy	Restricted stock units M-Exempt	Washburn Theodore James Jr. Principal Accounting Officer	Officer	2 695 Value: $78.7K
Mar 02, 2026 Buy	Common stock M-Exempt	Washburn Theodore James Jr. Principal Accounting Officer	Officer	2 450 Value: $71.5K
Mar 02, 2026 Sell	Common stock S-Sale	Washburn Theodore James Jr. Principal Accounting Officer	Officer	727 Value: $21.1K
Mar 02, 2026 Buy	Common stock M-Exempt	Washburn Theodore James Jr. Principal Accounting Officer	Officer	2 350 Value: $68.6K
Mar 02, 2026 Sell	Common stock S-Sale	Washburn Theodore James Jr. Principal Accounting Officer	Officer	698 Value: $20.2K
Mar 02, 2026 Buy	Restricted stock units M-Exempt	Washburn Theodore James Jr. Principal Accounting Officer	Officer	2 450 Value: $71.5K
Mar 01, 2026 Buy	Restricted stock units A-Award	Milanova Tsveta Chief Commercial Officer	Officer	14 000 Value: $387.5K
Mar 01, 2026 Buy	Stock options (right to buy) A-Award	Milanova Tsveta Chief Commercial Officer	Officer	52 000 Value: $1.57M
Mar 01, 2026 Buy	Stock options (right to buy) A-Award	Jones Cecilia Chief Financial Officer	C-Suite Officer	52 000 Value: $1.57M
Mar 01, 2026 Buy	Restricted stock units A-Award	Gheuens Sarah Chief Medical Officer	Officer	14 000 Value: $387.5K
Mar 01, 2026 Buy	Restricted stock units A-Award	Gheuens Sarah Chief Medical Officer	Officer	22 000 Value: $609.0K
Mar 01, 2026 Buy	Restricted stock units A-Award	Burns James William Chief Legal Officer	Officer	14 000 Value: $387.5K
Mar 01, 2026 Buy	Stock options (right to buy) A-Award	Burns James William Chief Legal Officer	Officer	52 000 Value: $1.57M
Mar 01, 2026 Buy	Restricted stock units A-Award	Goff Brian Chief Executive Officer	CEO / President	48 000 Value: $1.33M
Mar 01, 2026 Buy	Stock options (right to buy) A-Award	Goff Brian Chief Executive Officer	CEO / President	174 000 Value: $5.26M
Mar 01, 2026 Buy	Restricted stock units A-Award	Viswanadhan Krishnan Chief Corp Dev & Strategy	Officer	14 000 Value: $387.5K
Mar 01, 2026 Buy	Stock options (right to buy) A-Award	Viswanadhan Krishnan Chief Corp Dev & Strategy	Officer	52 000 Value: $1.57M
Mar 01, 2026 Buy	Stock options (right to buy) A-Award	Gheuens Sarah Chief Medical Officer	Officer	52 000 Value: $1.57M
Mar 01, 2026 Buy	Restricted stock units A-Award	Jones Cecilia Chief Financial Officer	C-Suite Officer	14 000 Value: $387.5K
Mar 01, 2026 Buy	Restricted stock units A-Award	Washburn Theodore James Jr. Principal Accounting Officer	Officer	8 452 Value: $234.0K
Jan 05, 2026 Buy	Common stock M-Exempt	Milanova Tsveta Chief Commercial Officer	Officer	8 475 Value: $232.6K
Jan 05, 2026 Sell	Common stock S-Sale	Milanova Tsveta Chief Commercial Officer	Officer	2 872 Value: $77.6K
Jan 05, 2026 Buy	Restricted stock units M-Exempt	Milanova Tsveta Chief Commercial Officer	Officer	8 475 Value: $232.6K
Dec 30, 2025 Sell	Common stock S-Sale	Burns James William Chief Legal Officer	Officer	2 932 Value: $79.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AGIOS PHARMACEUTICALS

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Ph...

Read Full Profile Here